Simtrazene

Simtrazene

SCHEMBL4971

CN(/N=N/N(C)c1ccccc1)c1ccccc1

nearest known ligand 0.48

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 8/20 0.48
KMT2A Q03164 8/20 0.48
MAPT P10636 6/20 0.48
RAB9A P51151 5/20 0.48
NPC1 O15118 4/20 0.48
MAPK1 P28482 4/20 0.48
SMN1; SMN2 Q16637 3/20 0.48
TNNI3 P19429 1/20 0.48
TNNT2 P45379 1/20 0.48
TNNC1 P63316 1/20 0.48
KEAP1 Q14145 1/20 0.48
NFE2L2 Q16236 1/20 0.48
HTT P42858 1/20 0.46
CASP3 P42574 1/20 0.44
SENP8 Q96LD8 1/20 0.44
SENP7 Q9BQF6 1/20 0.44
SENP6 Q9GZR1 1/20 0.44
FAAH O00519 1/20 0.44
PHGDH O43175 1/20 0.44
MGLL Q99685 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Simtrazene SCHEMBL6312204 1.00 MEN1 (0.48) MEN1KMT2AMAPTRAB9ANPC1
SCHEMBL13594601 0.87 MEN1 (0.44) MEN1KMT2AMAPTRAB9ANPC1
SCHEMBL15151253 0.83 KMT2A (0.64) MEN1KMT2AMAPTRAB9ANPC1
Simtrazene SCHEMBL28248614 0.82 RAB9A (0.39) MEN1KMT2AMAPTRAB9ANPC1
SCHEMBL12192668 0.81 MEN1 (0.41) MEN1KMT2AMAPTRAB9ANPC1
SCHEMBL301282 0.78 ALDH1A1 (0.56) MEN1KMT2AMAPTRAB9ANPC1
SCHEMBL13189723 0.78 MEN1 (0.42) MEN1KMT2AMAPTRAB9ANPC1
SCHEMBL7558901 0.78 KMT2A (0.50) MEN1KMT2AMAPTRAB9ANPC1
SCHEMBL9684406 0.76 ALDH1A1 (0.46) MEN1KMT2AMAPTRAB9ANPC1
SCHEMBL6979719 0.74 MEN1 (0.47) MEN1KMT2AMAPTRAB9ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Appears in 9879 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260116861-A1 ISOXAZOLE HYDROXAMIC ACIDS AS HISTONE DEACETYLASE 6 INHIBITORS THE GEORGE WASHINGTON UNIVERSITY, A CONGRESSIONALLY CHARTERED NOT-FOR-PROFIT CORPORATION (US) 2026-04-30 US claimed
US-12522572-B2 Isoxazole hydroxamic acids as histone deacetylase 6 inhibitors THE GEORGE WASHINGTON UNIVERSITY, A CONGRESSIONALLY CHARTERED NOT-FOR-PROFIT CORPORATION (US) 2026-01-13 US claimed
EP-4524131-A1 SMALL MOLECULES FOR TREATING CANCER, INHABITING CHEMOKINE ACTIVITY AND/OR INDUCING CELL DEATH AlonBio Ltd. (IL) 2025-03-19 EP claimed
US-12202803-B2 Small molecules for treating cancer, inhibiting chemokine activity and/or inducing cell death ALONBIO LTD. (IL) 2025-01-21 US claimed
US-20240343697-A1 ISOXAZOLE HYDROXAMIC ACIDS AS HISTONE DEACETYLASE 6 INHIBITORS THE GEORGE WASHINGTON UNIVERSITY, A CONGRESSIONALLY CHARTERED NOT-FOR-PROFIT CORPORATION (US) 2024-10-17 US claimed
US-12109219-B2 Cannabinoid receptor modulators ARENA PHARMACEUTICALS, INC. (US) 2024-10-08 US claimed
WO-2024162488-A1 PHARMACEUTICAL COMPOSITION COMPRISING CUCURBITACIN D FOR PREVENTING OR TREATING NEUROPATHIC PAIN 주식회사 재인알앤피 2024-08-08 WO claimed
EP-4401780-A1 AMORPHOUS PHOTOSENSITIZING PARTICLES, METHODS FOR THE PREPARATION THEREOF, AND METHODS FOR THE USE THEREOF University of Maryland, College Park (US) 2024-07-24 EP claimed
WO-2024026505-A2 DISRUPTION OF TELOCYTE ACTIVITY PATEL AMIT (US) 2024-02-01 WO claimed
US-20240002347-A1 SMALL MOLECULES FOR TREATING CANCER, INHIBITING CHEMOKINE ACTIVITY AND/OR INDUCING CELL DEATH ALONBIO LTD. (IL) 2024-01-04 US claimed
CN-1923173-A Anti-cancer drugs slow release agent comprising anticancer antibiotics and booster thereof JINAN KANGQUAN PHARMACEUTICAL (CN) 2007-03-07 CN claimed
CN-1857723-A Slow released anticancer medicine preparation with both amrubicin and its synergist KANGQUAN MEDICINE SCI TECH CO (CN) 2006-11-08 CN claimed
US-20060079472-A1 Methods for treating angiogenesis ANGIOSYN, INC. 2006-04-13 US claimed
US-20060024365-A1 Novel dosage form VAYA NAVIN 2006-02-02 US claimed
US-20060018933-A1 Novel drug delivery system TORRENT PHARMACEUTICALS LIMITED (IN) 2006-01-26 US claimed
US-20060018934-A1 Novel drug delivery system TORRENT PHARMACEUTICALS LIMITED (IN) 2006-01-26 US claimed
CN-1634584-A Anti-cancer medicine composition containing antimetabolite SHANDONG LANJIN BIOENGINEERING (CN) 2005-07-06 CN claimed
US-20040092583-A1 Treatment for inhibiting neoplastic lesions SHANAHAN-PRENDERGAST ELIZABETH (IE) 2004-05-13 US claimed
EP-1351678-A2 TREATMENT FOR INHIBITING NEOPLASTIC LESIONS USING INCENSOLE AND/OR FURANOGERMACRENS Shanahan-Prendergast, Elizabeth (IE) 2003-10-15 EP claimed
WO-2002053138-A2 TREATMENT FOR INHIBITING NEOPLASTIC LESIONS USING INCENSOLE AND/OR FURANOGERMACRENS SHANAHAN-PRENDERGAST ELISABETH (IE) 2002-07-11 WO claimed